Analytical Data
-
Gene name
GAD2/GAD65
- Application
-
Alternative Names
GAD65; Glutamate Decarboxylase 2, Acid; Pancreatic Islets And Brain,65kDa; 65 kDa glutamic acid decarboxylase; Glutamate decarboxylase 65 kDa isoform
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q05329
-
Expression Region
Arg65~Arg105
-
Molecular Weight
34kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GAD2 (Glutamic Acid Decarboxylase 2) and GAD65 are key enzymes involved in the synthesis of gamma-aminobutyric acid (GABA), an important inhibitory neurotransmitter in the central nervous system. Dysregulation of GAD65 has been implicated in various neurological disorders, including epilepsy, anxiety, and schizophrenia. The study of GAD2/GAD65 recombinant proteins has gained significance in the context of developing targeted therapies and understanding pathophysiological mechanisms underlying these conditions. Recombinant protein technology allows for the production of high yields of purified GAD2 and GAD65, facilitating detailed biochemical and pharmacological studies. Investigating the structure, function, and interaction of these enzymes can provide insights into their role in neurotransmitter metabolism and help in designing specific inhibitors or activators to modulate GABAergic signaling. Furthermore, research into GAD2/GAD65 has therapeutic implications, including the potential use of these proteins in immunotherapy for autoimmune conditions, such as type 1 diabetes, where antibodies against GAD65 are often present. Overall, the recombinant expression of GAD2 and GAD65 serves as a foundation for advancing our understanding of GABAergic dysfunctions, paving the way for innovative therapeutic strategies.
